Want to see HAE full AI Analyst Report?
HAE Stock Chart & Stats
$61.62
-$0.34(-0.44%)
At close: 4:00 PM EST
$61.62
-$0.34(-0.44%)
Day’s Range― - ―
52-Week Range$47.32 - $87.32
Previous CloseN/A
Volume53.78K
Average Volume (3M)902.72K
Market Cap
$3.46B
Enterprise Value$4.28B
Total Cash (Recent Filing)$245.44M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)37.2
Beta0.50
Next Earnings
Aug 06, 2026EPS Estimate
1.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.04
Shares Outstanding45,445,984
10 Day Avg. Volume570,684
30 Day Avg. Volume902,718
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)3.20
Price to Sales (P/S)1.91
P/FCF Ratio9.79
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue3.21
Enterprise Value/Gross Profit5.60
Enterprise Value/Ebitda15.29
Forecast
1Y Price Target
$78.00Price Target Upside26.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)5.22
Revenue Forecast (FY)$1.40B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelHaemonetics’ installed base and consumable-heavy model (aperesis machines plus high-volume single-use kits) creates durable, procedure-linked recurring revenue. This drives predictable top-line pull-through, supports margin sustainability and eases forecasting for at least the next several quarters.
Strong Cash Generation & FCFRobust operating cash flow and high free cash flow conversion (FCF covered most net income; strong multi-year cumulative FCF) provide durable internal funding for R&D, commercialization, buybacks, and debt servicing. This enhances financial flexibility through near-term volatility.
Regulatory Wins & LaunchesRecent clearances and product rollouts (Persona PLUS, VASCADE expansions, Device360) strengthen clinical differentiation and drive adoption in plasma and hospital markets. These approvals and commercialization plans support sustainable share gains and durable revenue growth across core franchises.
Bears Say
Elevated LeverageMaterial increase in leverage and a sizeable debt load make the company more sensitive to higher interest costs and limit strategic optionality. Elevated net leverage constrains capital allocation and raises refinancing and covenant risk over the coming 2–6 months if cash generation softens.
Margin Compression & Earnings VolatilityDespite strong gross margins, sizable net-margin deterioration and earnings volatility reduce retained earnings and ROE. Persistent cost headwinds (tariffs, mix, acquisition dilution) could limit sustainable margin recovery and weaken long-term profitability unless structural cost saves are realized.
Acquisition Dilutive & Portfolio ShiftsNear-term dilution from Vivasure, plus prior divestitures that reduced reported revenue, create mix and earnings drag and add execution risk for launches (PerQseal Elite excluded from guide). Integration, launch timing and mix shifts could restrain organic margin and revenue momentum over months.
Haemonetics News
HAE FAQ
What was Haemonetics’s price range in the past 12 months?
Haemonetics lowest stock price was $47.31 and its highest was $87.32 in the past 12 months.
What is Haemonetics’s market cap?
Haemonetics’s market cap is $3.46B.
When is Haemonetics’s upcoming earnings report date?
Haemonetics’s upcoming earnings report date is Aug 06, 2026 which is in 24 days.
How were Haemonetics’s earnings last quarter?
Haemonetics released its earnings results on May 07, 2026. The company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.273 by $0.017.
Is Haemonetics overvalued?
According to Wall Street analysts Haemonetics’s price is currently Undervalued.
Does Haemonetics pay dividends?
Haemonetics does not currently pay dividends.
What is Haemonetics’s EPS estimate?
Haemonetics’s EPS estimate is 1.09.
How many shares outstanding does Haemonetics have?
Haemonetics has 45,445,984 shares outstanding.
What happened to Haemonetics’s price movement after its last earnings report?
Haemonetics reported an EPS of $1.29 in its last earnings report, beating expectations of $1.273. Following the earnings report the stock price went up 3.228%.
Which hedge fund is a major shareholder of Haemonetics?
Currently, no hedge funds are holding shares in HAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haemonetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$78.00 (26.58% Upside)
$78.00 (26.58% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 71.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.7%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.53%
12-Months-Change
Fundamentals
Return on Equity
11.32%
Trailing 12-Months
Asset Growth
-2.24%
Trailing 12-Months
Company Description
Haemonetics
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
HAE Company Deck
HAE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong achievements: solid organic revenue growth (notably in plasma and blood management), full-year margin expansion, robust free cash flow and disciplined capital allocation, plus important product approvals and commercialization progress (Persona PLUS, VASCADE MVP XL and Vivasure acquisition). Notable near-term headwinds were acknowledged, including a weak interventional technologies performance, Q4 margin pressure driven by tariffs and transition effects, Vivasure dilution, and higher tax/interest costs. Management provided constructive FY2027 guidance (revenue growth and margin expansion), emphasized most large portfolio transitions are behind them, and outlined clear commercialization and launch plans. Overall, the positive operational and financial momentum and confident guidance outweigh the manageable near-term challenges.View all HAE earnings summariesHAE Stock 12 Month Forecast
Average Price Target
$78.00
▲(26.58% Upside)
Technical Analysis
Ownership Overview
1.84% Insiders
38.45% Mutual Funds
0.18% Other Institutional Investors
31.10% Public Companies and
Individual Investors